Background and Aims: arginin vasopressin (aVp) is apotent vasoconstrictor whichhas been used in vasodilatoryshock when therapy with catecholamines and fluids has failed. In this studyw ee valuated the association of AV Pw ith organ failure and mortality in cardiac surgical patients suffering from vasodilatory shock refractory to norepinephrine (ne) treatment.
INTRODUCTION
Cardiopulmonary bypass (CPB) sometimes induces av asodilatory shock in which release of inflamma-strictor which has been used to restorevascular tone in hypotensive states including cardiac arrest, septic, postcardiotomy andhemorrhagic shock and intraoperative hypotension (6, 7, 8, 9) . Asingle dose of AV P is included into the Advanced Cardiac Life-Support resuscitation guidelines (10) . AV Ps timulatesV 1-receptors of vascular smooth muscle and hence increases cytoplasmic ionized calcium leading to vasoconstriction (11) . AV Pc an also induce vasoconstriction by blockinga ctivated ATP/potassium cannels within the muscle cell membranea nd facilitating myocytedepolarization (12) .
AV Pi sap otent vasoconstrictor of skin, skeletal muscle, fat, pancreas and thyroid gland. The effect is less potentincoronary,mesenteric and renal circulation. AV Ph as little effect on blood pressureu nder normal conditions (13, 14,1 5) . Impaired liver function and 50% mortality has been reported despite improved cardiocirculatory functioninadvanced vasodilatorys hocki np atients of which almost 50% werecardiac surgical (16) .
Therei so nly sparse data on the effect of AV Po n outcome after cardiacsurgery hence we evaluated the outcome of cardiac surgical patientsr eceiving AV P during aone year observation period.
METHODS
This study was approved by the Institutional Review Board. Data wereprospectively collectedonA VP-treated patients after cardiac surgery between January first, 2004 and December 31, 2004 at HelsinkiU niversity Hospital (17) . The total number of patients treated in the cardiac surgical intensive careunit (ICU) during this observation period was 857 and 33 of those patients received AV Pi nfusion (Pitressin ® Pfizer,Karlsruhe, Germany) in addition to norepinephrine infusion (AVP group). We also retrospectively identified from the database 33 patients who received equal doses of norepinephrine compared to patients receiving AV Pw hen AV Pi nfusion was started and these patients served as controls (NE group). The indication to start AV P infusion was failuretorestorecardiovascular stabilitywith norepinephrine and fluid resuscitation within the first 24 hours after onset of operation. Most patients received a1 IU bolus of AV Pand the initial dose was 1I U/ hour after which the infusion rate was titrated according to clinical need but adose >0.04 IU /kg was avoided.
Data on hemodynamics and medication was automatically collected in our critical carecomputerized data base. The patients' demographics and risk factors according to the EuroSCORE model (18) werea lso registered. The predicted mortalitywas assessed according to logistic EuroS-CORE (19) . The data was thereafter supplemented with postoperative daily SOFAscoring (Sequential Organ Fail-ureAssessment) (20) , information on postoperative cardiac complications, length of stay in ICU, 30 day, 60 day and six month mortality.Other complicationsincluded in our data wereresternotomy due to bleeding or ischemia, renal failuren ecessitating renal replacement therapy or ac ontinuous infusion of furosemide togetherw ith at least doubled plasma creatinine value, stroke, new epileptic symptoms or delirium, infections in the ICU, and respiratory failure requiring prolonged ventilator support.
Demographic and procedural characteristics and the two risk scores werecompared between the groups by parametric and nonparametric analyses (t-test and Wilcoxon rank sum test for continuousand Cochran-Mantel-Haenszel test forcategorical data). Due to small cell frequencies,Fisher's exact test (one-sided) was applied when incidence of mortality and complications werea nalyzed. The results are reported as mean and standarddeviation (SD) or frequencies. AP-value <0.05 was considered significant.
RESULTS
Patient data and operative characteristics arep resented in Table 1and the mortality data and complications arep resentedi nT able 2. The mean SOFA scoreo nt he first day was 8,7 ±1,3 in the AV Pgroup and 9,6 ±2,5 in the NE group, and on the thirdd ay 11,2 ±3,1 and 10,2 ±2,5, respectively.Length of stay in the ICU (ICULOS)did not differ between the groups, mean ICULOS was 12,6 ±10d ays in the AV Pg roup and 15,1 ±7,3 days in the NE group. Renal replacement therapy (RRT) was used in 10 of 12 renal failure AV Ppatients and in 2of3inthe NE group. Twopatients receiving RRTdied in the AV Pgroup and one in the NE group. Pneumonia was diagnosed in five patients in the AV Pgroup and in one in the NE group. The only patient in the NE group who had infection during ICU stay had apositive blood culture (staphy loccusa ureus).T wo patients in the AV Pg roup with infection died. Twop atients in the AV Pg roup and one patient in the NE group had active endocarditis preoperatively.
The vasoactive medication and the maximal doses arep resented in Table 3 . In addition to norepinephrine, epinephrine and milrinone, one patient in the AV Pgroup and two patients in the NE group received dopamine, Dobutamine was used in one patient in the NE group. One patient in the AV Pgroup and two patients in the NE-group received levosimendan. The mean dose of norepinephrineatthe start of vasopres- Transplantations  44  Others  23  IABP  13 13  13  7  Resternotomy  10  10 10  4  Emergency operation  16  15  16 15 16 15
CABG=coronary arteryb ypassg rafting,A VR =aortic valve replacement, MVR =mitral valve reconstruction, IABP =i ntra-aortic balloonpump sin infusion was 0,27 ±0,15microg/kg/min. The mean duration of AV P-infusionw as 48 ±45h ours (range 2-169) and the mean dose was 2,7 IU ±1,8 (range 1-9). AV Pincreased mean arterial pressurebut had no impact on cardiac performance ( Table 4) . None of our patients receiving AV Pl ess than 2I U/h died. Two patients in the AV Pgroup who had complicated aortic dissection died in the ICU, three ICU deaths were due to surgical reasons and two patients with critical preoperative condition died from multi organ failure (MOF). In the NE group, one of the two patients who died during ICU stay, died due to postoperative myo-cardiali nfarction (graft failure) and the other one underwent double valve operation resultinginheart failureand finally MOF.
DISCUSSION
We have demonstrated that AV Pdid not increase predicted mortality in cardiac surgical patients suffering from vasodilatory shock unresponsive to norepinephrine therapy.Renal and infection complications were moref requent after AV Pc omparedw ith patients treated with NE alone. AV Pd id not increase neurological or cardiovascular complications. Both ICU and 30day mortality in our AV Ppatients was lower than in aprevious report by Luckner (16), who reported a50% mortality in general surgical ICU patientsw ith advanced vasodilatory shock. Forty percent of their patients had postcardiotomy shock, but mortality in this particular group was not presented separately.T he observed mortality in our study in AV Pa nd NE groups was lower than predicted. It seems that high dose vasopressor therapy itself in this patient population does not increase mortality.
In our material adding AV Pt ot he treatment protocol did not increase cardiovascularc omplications. It has been shown that in ap ostcardiotomy shock vasopressin increases meana rterial blood pressure Hemodynamic parametesinpatients treated with vasopressin and norepinephrine at the start of infusion (VP1), at the highest dose of vasopressin (VP2) and in patients treated only with norepinephrine at the highest dose (NE), mean and SD. *V alues at VP2 compared with values at VP1, p>0,05.
VP2 NE CI (l/min/m 2 )2 ,9 +0,9 2,6 +0,8 2,7 +0,9 MAP (mmHg) 61 61 61 +9 70 +14* 75 +11 SVI (ml/m 2 )2 8+8 25 +80 29 +11 PCWP (mmHg) 15 15 15 +4 16 +50 12 +40 SVRI(dyn ·s/cm 5 /m 2 )1 468 +511 5111 710 +611* 0 1900 +7700 CI =cardiac index, MAP=meanarterial blood pressure, SVI =stroke volume index, PCWP =pulmonary artery wedge pressure andhencehelpstomaintain coronary perfusion pressure(7, 16). Thisfinding is supported by animal data. Isolatedmonkey coronary arteries relaxed after vasopressin (21) . In pigs resuscitated with vasopressin both coronary and cerebral perfusion blood flow increased as well left ventricular blood flow and total cerebral flow (22) . Patients in both groups received high doses of norepinephrine and weret hereforea t risk for complications associated with NE treatment. Ashort term vasopressin infusion decreased significantly the need of NE during severeseptic shock (23) . Norepinephrine dependency has been shown to be a predictor of poor outcomeincardiac surgical patients with prolonged intensive carestay (24) . NE has been known to have both cardiotoxic and proarrhythmic effects (4).
Our protocol may partly explain the low mortality. We used av ery low dose and started gradually the infusion (23) . The mean dose of vasopressin was below to the recommended dose 0.04 IU/min (25) . Most patients wereg iven ab olus dose of AV Pino rder to test their response to the drug, and acontinuous infusion was started to responders only.The safetyoflow dose AV Pc ombined to NE is supported by the fact that none of patients receiving AV Pb elow 2U/h died.
Organ failures assessed by SOFAs coring system weres imilar both after AV P+NE treatment and NE alone. In previous reports, AV Pt reatment has been associated with an increase in liver enzymes and bilirubin, and ad ecrease in platelet count (16) . Both bilirubin and platelet count arei ncluded to total SOFAscores (20) . In apost-mortem analysis non-occlusive mesenteric ischemia or acute hypoxic liver failurew erer arefi ndings and not as ignificant contributortomortality in patients treated with AV P (16) . In aprospectivestudy,infusion of AV P+NE preserved gastrointestinal perfusion better than NE alone (26) Our AV Pp atients had morer enal complications than patients treated with NE alone. Our finding agrees with those by Luckner et al. In their patient population with advanced vasodilatory shock 79% of patients needed continuous hemofiltration (16) . In an animal study increasing doses of AV Pr educed both renalbloodflow velocity and renal corticalflow (27) . In cardiac surgical patients postoperative norepinephrine alone didn't increase serum creatinine concentrations (28) . Renal replacement therapy is associated with increased mortality in cardiac surgical patients (29) , but therewereonly 20% mortality in our AV Pg roup in patients with renal failurer eceiving RRTand one death in patients with renal failurebut without RRT.
Infection complications werealso morecommon in patientstreated with AV P. Twopatients in AV Pgroup and one in NE group wereoperated because of active endocarditis. We have no reasonable explanation for the high incidenceofinfections in AV Pgroup. Predisposing factors might be the higher number of resternotomies due to bleeding and the use of IABP (intra aortic balloon pump) in AV Pp atients. Both of these processes areassociated with an increased risk of infection (30, 31) . Morepatients in AV Pgroup werealso critically ill preoperatively (32) .
To include ar etrospectively collected control group is problematicand thereare several confounding factors-not only vasopressin-affecting outcome of these patients. The patients werei nb oth groups very critical cardiac surgical patientsr eceiving several vasoactivedrugs, not only NE and AV P. In addition, use of IABP and number of resternotomies were morecommon in patientsreceiving AV P. In fact, it is impossible to find equal control patientswhom AV P administrationisindicated, not eveninaprospective study.Hence, to include aretrospective collected control groups can be acceptable. In this study,ac omparison between the two groups is moredescriptive than statistical.
In conclusion, AV Pi nfusion after cardiac surgery did not increase predicted mortality despite the fact that renal and infection complications werec ommon.
